Advertisement Mylan resolves Caduet tablets patent dispute with Pfizer - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Mylan resolves Caduet tablets patent dispute with Pfizer

Mylan has signed a settlement agreement with Pfizer to resolve litigation related to Caduet tablets, 2.5mg/10, 2.5mg/20mg, 2.5mg/40mg, 5mg/10mg, 5mg/20mg, 5mg/40mg, 5mg/80mg, 10mg/10mg, 10mg/20mg, 10mg/40mg and 10mg/80mg.

Mylan said that the generic name of Caduet tablets is Amlodipine Besylate/Atorvastatin Calcium tablets.

Pursuant to the settlement agreement, pending litigation will be dismissed and Mylan may begin to market and sell a generic version of Caduet on 30 Nov 2011, or earlier under certain circumstances.

Additional details of the settlement are confidential, and the agreement itself is subject to review by the US Department of Justice and the Federal Trade Commission.